SAN DIEGO, July 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report tomorrow the interim efficacy results from the company’s Phase 2 trial evaluating the potential for its TransVax(tm) therapeutic DNA vaccine to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell transplant recipients. CMV and organ transplant expert Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology, and Vice Chair of Research in Surgery at the Indiana University School of Medicine, is scheduled to join Vical management on the call.
